Network meta-analysis for deaths_(OS)

Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence of assessment of transitivity assumption plausibility. Calculations by netmeta package.

Evidence network for deaths_(OS)

3KEYNOTE-119 (PDL1 CPS>1), 2019 KEYNOTE-119 (PDL1 CPS>10), 2019 KEYNOTE-119 (all population), 20191EMBRACA, 20181OlympiAD, 20172ASCENT (all population), 2021 ASCENT (patients without brain metastases), 2021olaparib vs. pembrolizumab alone 1.00 [0.71; 1.39]1.00 [0.71;1.39]olaparib vs. pembrolizumab alone 1.00 [0.71; 1.39]olaparib vs. sacituzumab govitecan sacituzumab govitecan better 1.82 [1.28; 2.57]1.82 [1.28;2.57]olaparib vs. sacituzumab govitecan sacituzumab govitecan better 1.82 [1.28; 2.57]olaparib vs. Standard of Care (SoC) 0.90 [0.66; 1.23]0.90 [0.66;1.23]olaparib vs. Standard of Care (SoC) 0.90 [0.66; 1.23]olaparib vs. talazoparib 1.06 [0.72; 1.57]1.06 [0.72;1.57]olaparib vs. talazoparib 1.06 [0.72; 1.57]pembrolizumab alone vs. olaparib 1.00 [0.72; 1.40]1.00 [0.72;1.40]pembrolizumab alone vs. olaparib 1.00 [0.72; 1.40]pembrolizumab alone vs. sacituzumab govitecan sacituzumab govitecan better 1.82 [1.50; 2.21]1.82 [1.50;2.21]pembrolizumab alone vs. sacituzumab govitecan sacituzumab govitecan better 1.82 [1.50; 2.21]pembrolizumab alone vs. Standard of Care (SoC) 0.90 [0.80; 1.02]0.90 [0.80;1.02]pembrolizumab alone vs. Standard of Care (SoC) 0.90 [0.80; 1.02]pembrolizumab alone vs. talazoparib 1.06 [0.82; 1.39]1.06 [0.82;1.39]pembrolizumab alone vs. talazoparib 1.06 [0.82; 1.39]sacituzumab govitecan vs. olaparib sacituzumab govitecan better 0.55 [0.39; 0.78]0.55 [0.39;0.78]sacituzumab govitecan vs. olaparib sacituzumab govitecan better 0.55 [0.39; 0.78]sacituzumab govitecan vs. pembrolizumab alone sacituzumab govitecan better 0.55 [0.45; 0.67]0.55 [0.45;0.67]sacituzumab govitecan vs. pembrolizumab alone sacituzumab govitecan better 0.55 [0.45; 0.67]sacituzumab govitecan vs. Standard of Care (SoC) sacituzumab govitecan better 0.50 [0.43; 0.58]0.50 [0.43;0.58]sacituzumab govitecan vs. Standard of Care (SoC) sacituzumab govitecan better 0.50 [0.43; 0.58]sacituzumab govitecan vs. talazoparib sacituzumab govitecan better 0.58 [0.44; 0.77]0.58 [0.44;0.77]sacituzumab govitecan vs. talazoparib sacituzumab govitecan better 0.58 [0.44; 0.77]Standard of Care (SoC) vs. olaparib 1.11 [0.81; 1.52]1.11 [0.81;1.52]Standard of Care (SoC) vs. olaparib 1.11 [0.81; 1.52]Standard of Care (SoC) vs. pembrolizumab alone 1.11 [0.98; 1.25]1.11 [0.98;1.25]Standard of Care (SoC) vs. pembrolizumab alone 1.11 [0.98; 1.25]Standard of Care (SoC) vs. sacituzumab govitecan sacituzumab govitecan better 2.02 [1.74; 2.35]2.02 [1.74;2.35]Standard of Care (SoC) vs. sacituzumab govitecan sacituzumab govitecan better 2.02 [1.74; 2.35]Standard of Care (SoC) vs. talazoparib 1.18 [0.93; 1.49]1.18 [0.93;1.49]Standard of Care (SoC) vs. talazoparib 1.18 [0.93; 1.49]talazoparib vs. olaparib 0.94 [0.64; 1.39]0.94 [0.64;1.39]talazoparib vs. olaparib 0.94 [0.64; 1.39]talazoparib vs. pembrolizumab alone 0.94 [0.72; 1.23]0.94 [0.72;1.23]talazoparib vs. pembrolizumab alone 0.94 [0.72; 1.23]talazoparib vs. sacituzumab govitecan sacituzumab govitecan better 1.71 [1.29; 2.26]1.71 [1.29;2.26]talazoparib vs. sacituzumab govitecan sacituzumab govitecan better 1.71 [1.29; 2.26]talazoparib vs. Standard of Care (SoC) 0.85 [0.67; 1.07]0.85 [0.67;1.07]talazoparib vs. Standard of Care (SoC) 0.85 [0.67; 1.07]Standard of Care (SoC)pembrolizumab alonetalazoparibolaparibsacituzumab govitecandirect evidencenetwork meta-analysis
T vs. C Standard of Care (SoC)pembrolizumab alonetalazoparibolaparibsacituzumab govitecan
Standard of Care (SoC)---1.11
0.98; 1.25		1.18
0.93; 1.49		1.11
0.81; 1.52		2.02
1.74; 2.35
pembrolizumab alone0.90
0.80; 1.02		---1.06
0.82; 1.39		1.00
0.72; 1.40		1.82
1.50; 2.21
talazoparib0.85
0.67; 1.07		0.94
0.72; 1.23		---0.94
0.64; 1.39		1.71
1.29; 2.26
olaparib0.90
0.66; 1.23		1.00
0.71; 1.39		1.06
0.72; 1.57		---1.82
1.28; 2.57
sacituzumab govitecan0.50
0.43; 0.58		0.55
0.45; 0.67		0.58
0.44; 0.77		0.55
0.39; 0.78		---

pathologies: 270,140,240 - treatments: 1232 result logic

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons